Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 29-41 , March 2008

New approaches in acute myeloid leukemia

  • William Blum, MD (Assistant Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 614 293 9273; Fax: +1 614 293 7526.
    • ,
  • Guido Marcucci, MD (Associate Professor of Medicine)

References 

  1. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Reviews. 2004;18:115–136
  2. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood. 2007;109:431–448
  3. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. The New England Journal of Medicine. 2004;350:1605–1616
  4. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. The New England Journal of Medicine. 2004;350:1617–1628
  5. Radmacher MD, Marcucci G, Ruppert AS, et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006;108:1677–1683
  6. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336
  7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333
  8. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  9. Ghaddar HM, Plunkett W, Kantarjian HM, et al. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994;8:1269–1274
  10. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research. 1998;58:4173–4179
  11. Koo HM, Monks A, Mikheev A, et al. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Research. 1996;56:5211–5216
  12. Koo HM, McWilliams MJ, Alvord WG, et al. Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. Cancer Research. 1999;59:6057–6062
  13. Neubauer A, Maharry K, Marcucci G, et al. Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: a Cancer and Leukemia Group B (CALGB) study. Journal of Clinical Oncology. 2005;23:563s;[abstract 6514] Ref Type: Electronic Citation
  14. Schlenk RF, Dohner K, Pralle H, et al. Risk-adapted therapy in younger adults with acute myeloid leukemia: Results of the AMLHD98a trial of the AMLSG. Blood. 2006;108:8a;[abstract 14]
  15. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658–3665
  16. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–1542
  17. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759
  18. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–4380
  19. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335
  20. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood. 2006;108:50a;[abstract 157]
  21. DeAngelo DJ, Amrein PC, Kovacsocics TJ, et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood. 2006;108:51a;[abstract 158]
  22. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006;108:3674–3681
  23. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Journal of Clinical Oncology. 1999;17:3767–3775
  24. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Journal of Clinical Oncology. 2005;23:5705–5717
  25. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 2006;24:3904–3911
  26. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865–2870
  27. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752–759
  28. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. Journal of Clinical Oncology. 2005;23:3971–3993
  29. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research. 2006;66:6361–6369
  30. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271–3279
  31. Blum W, Klisovic RB, Hackanson B, et al. Clinical, pharmacokinetic, and pharmacodynamic results of a phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology. 2007;
  32. Cashen A, Schiller GJ, Larsen JS, et al. Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML). Blood. 2006;108:561a;[abstract 1984]
  33. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research. 2001;61:131–137
  34. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387–1394
  35. Harousseau JL, Lancet JE, Reiffers J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007;109:5151–5156
  36. Ishiguro K, Seow HA, Penketh PG, et al. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Molecular Cancer Therapeutics. 2006;5:969–976
  37. Baumann RP, Seow HA, Shyam K, et al. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncology Research. 2005;15:313–325
  38. Giles F, Verstovsek S, Faderl S, et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research. 2006;30:1591–1595
  39. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology. 2007;25:25–31
  40. Wei X, Dai G, Liu Z, et al. Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. The AAPS Journal. 2006;8:E743–E755
  41. Wei X, Dai G, Marcucci G, et al. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharmaceutical Research. 2006;23:1251–1264
  42. Klisovic RB, Blum W, Wei X, et al. A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results. Blood. 2005;106:782a;[abstract 2790]
  43. Gandhi V, Plunkett W, Bonate PL, et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clinical Cancer Research. 2006;12:4011–4017
  44. Burnett AK, Baccarani M, Johnson P, et al. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood. 2006;108:130a;[abstract 425]
  45. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105:940–947
  46. Debenham PG, Kartner N, Siminovitch L, et al. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Molecular and Cellular Biology. 1982;2:881–889
  47. Nussler V, Pelka-Fleischer R, Zwierzina H, et al. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia. 1996;10(Suppl 3):S23–S31
  48. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology. 1993;11:1652–1660
  49. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100:1224–1232
  50. Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006;106:830–838
  51. Shimizu S, Eguchi Y, Kamiike W, et al. Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene. 1996;12:2251–2257
  52. Capaccioli S, Quattrone A, Schiavone N, et al. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines. Oncogene. 1996;13:105–115
  53. Raveche ES, Salerno E, Scaglione BJ, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood. 2007;109:5079–5086
  54. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:13944–13949
  55. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. The New England Journal of Medicine. 2005;353:1793–1801
  56. Karakas T, Maurer U, Weidmann E, et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Annals of Oncology. 1998;9:159–165
  57. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003;101:425–432
  58. Marcucci G, Stock W, Dai G, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Journal of Clinical Oncology. 2005;23:3404–3411
  59. Marcucci G, Moser B, Blum W, et al. A phase III randomized trial of intensive induction and consolidation chemotherapy±oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. Journal of Clinical Oncology. 2007;25:360s;[abstract 7012]
  60. Chang BS, Kelekar A, Harris MH, et al. The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L). Molecular and Cellular Biology. 1999;19:6673–6681
  61. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26:2374–2380
  62. Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007;109:4441–4449
  63. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399–404
  64. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clinical Cancer Research. 2005;11:8403–8412
  65. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clinical Cancer Research. 2007;13:4467–4473
  66. Attar EC, De Angelo DJ, Sirulnik A, et al. Addition of bortezomib (velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate. Blood. 2005;106:780a;[abstract 2782]
  67. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102:4277–4283
  68. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood. 2006;108:8a;[abstract 13]
  69. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717–3721
  70. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105:986–993
  71. Roboz GJ, Giles FJ, List AF, et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006;20:952–957
  72. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research. 2004;10:3577–3585
  73. Kurtin S, Sokol L. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer Control. 2006;13(Suppl):26–31

PII: S1521-6926(07)00099-0

doi: 10.1016/j.beha.2007.11.009

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 29-41 , March 2008

Article Tools